It was also reported that the PD-1 depleted CAR-T cells by CRISPR/Cas9 system displayed enhanced anti-tumor efficacy against hepatocellular carcinoma (HCC) (70). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.